"The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity. In a statement issued Friday, Metsera said Pfizer will acquire the company for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right entitling holders to additional payments of up to $20.65 per share in cash."
"U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy. Metsera, based in New York, has no products on the market, but it is developing oral and injectable treatments."
Pfizer agreed to acquire development-stage obesity drugmaker Metsera for up to $86.25 per share, combining $65.60 per share in cash with a contingent value right offering up to $20.65. Metsera has no marketed products but is developing oral and injectable treatments that could target obesity and diabetes. Pfizer pursued the acquisition after ending development of a potential obesity pill and faced a bidding contest with Novo Nordisk, which raised its offer before withdrawing. Metsera cited U.S. antitrust risks in Novo's bid and determined Pfizer's terms offered greater value and certainty of closing; Pfizer expects to close after a Nov. 13 shareholder meeting.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]